Sepsis Early EvaluatioN Through Rapid Ultrasound and veNous Gas Analysis
NCT ID: NCT05787184
Last Updated: 2023-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
400 participants
OBSERVATIONAL
2023-01-01
2024-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The rationale of this study is to improve early identification of septic patients who are at risk of rapid deterioration in the course of their permanence in the ER and the hospital wards in general. The investigators selected a number of clinical, laboratory and bedside ultrasound parameters which have been previously shown to be correlated with mortality in sepsis, and will seek to identify which among these parameters best correlates with prognosis when acquired in the very first minutes of a patient's arrival in the ER. The objective would be to analyse these parameters and eventually to propose a new early sepsis score which might help the emergency physician to better tailor its efforts and clinical resources to the most sick patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Role of Early Point of Care Ultrasound in Management of Sepsis in Emergency Department
NCT05849194
Use of Presepsin in the Emergency Department
NCT06150092
Prognostic Evaluation Of Severe Sepsis And Septic Shock. Procalcitonin Versus Delta Sofa
NCT01841190
Evaluation of Impaired Microcirculation During Septic Shock With Contrast Enhanced Ultrasound
NCT02277977
Evaluation of Parameters Collected From Routine Data for the Diagnosis of Sepsis and Septic Shock and Their Influence on Time to Diagnosis and Patient Outcome
NCT05383963
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
These patients will undergo a regular emergency room (ER) visit, during which a venous blood gas and a bedside ultrasound will be obtained, along with the collection of anamnestic and clinical parameters. All of these procedures normally take place in the first medical evaluation in the ER, therefore no unnecessary procedures or harm to patients will take place.
The data which will be obtained during the first medical visit include:
Anamnestic and demographic data:
* Age;
* Sex;
* History of hypertension, diabetes, congestive heart failure, chronic lung disease, chronic kidney failure, severe immunosuppression, cancer;
* Infective source, if known or suspected.
Vital parameters:
* Glasgow Coma Scale (GCS) and AVPU scale;
* Systolic, diastolic and mean arterial blood pressure;
* Heart and respiratory rate;
* Body temperature;
* Capillary refill time (CRT);
* Peripheral oxygen saturation and oxygen supplementation if present.
Venous blood gas analysis:
* pH;
* glucose;
* lactate;
* hemoglobin;
* sodium and potassium.
Bedside ultrasound examination:
* inferior vena cava distensibility through visual gestalt;
* global left ventricular contractility through visual gestalt;
* mitral annular plane systolic excursion (MAPSE), obtained through apical 4-chamber view.
All the above mentioned data will be obtained and reported in a specific module and subsequently added to the database.
Following the first medical visit, patients will prosecute their clinical course with diagnostic and therapeutic strategies as chosen by the attending emergency physicians. No additional maneuvers will take place as far as study procedures are concerned.
After a week from the enrollment, two physicians responsible for the study procedures (L.F. and G.T.) will manually extract clinical and laboratory data concerning the enrolled patients from the digital Health System softwares of the involved Hospitals. Data concerning death during hospital stay, ICU or regular ward admission, laboratory values, eventual positivity of blood culture, etc will be obtained and added to the study database.
The data which will be obtained at a week from enrollment are:
* Patient outcome: mortality, ICU or general ward admission;
* Results of blood cultures or other cultures from relevant specimens, if available;
* Results of blood tests performed during the first evaluation in the ER, including: white blood cell count (WBC), hematocrit, creatinine, C-reactive protein (CRP), Procalcitonin.
The last set of data concerning mortality will be obtained at 30 days, whether in-hospital (through the electronic hospital record) or out-of-hospital by telephone call.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pregnancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
FRANCESCHI FRANCESCO
Professor Francesco Franceschi, Head of the Emergency Medicine Department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fondazione Policlinico Universitario "A. Gemelli", IRCCS; Emergency Department
Rome, Lazio, Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4925
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.